Innovation at Terumo

Terumo Injection Filter Needle

A first step of the INFINO™ Development Program

Our Terumo Injection Filter Needles are intended for hypodermic and intravitreal injections and include an integrated 5μm polyamide mesh filter in the hub, intended to prevent intrinsic and extrinsic particles from being injected into the patient. Designed to provide a needle developed to enable injection of parental fluids for treatment of a growing number of eye diseases such as neovascular age-related macular degeneration, diabetic retinopathy and retinal vein occlusions.

PLAJEX™ COP Syringe with i-coating ™ Technology

Our PLAJEX™ Cyclo Olefin Polymer (COP) syringe represents a leap in primary packaging for sensitive drug formulations, particularly biologics. Its breakthrough i-coating ™ technology eliminates the need

for silicone oil, significantly reducing protein aggregation and particle formation. This innovation ensures drug integrity, enhances patient safety, and streamlines the development of new, complex therapies.

PLAJEX™ Ready-to-Fill Polymer Syringe with Tapered Needle

Integrating proprietary tapered needle technology with a robust silicone oil-free polymer syringe, Terumo Medical Care Solutions – Pharmaceutical produced an advanced RTF polymer syringe system that reduces injection forces without compromising patient comfort. Featuring a polymer-based barrel with excellent strength and clarity, and Terumo - Pharmaceutical’s proprietary i-coating™ technology on the stopper, the silicone oil-free syringe system is designed to preserve sensitive biotherapeutics¹.

_{1 Functional Evaluation and Characterization of a Newly Developed Silicone Oil-Free Prefillable Syringe System, Yoshino et al (2014) J Pharm Sc, 103: 1520-1528}

Nanopass™ 34G

The Nanopass™ 34G is the world's thinnest double-tapered 34G pen needle¹, redefining patient comfort for self-injections. Designed for the subcutaneous (SC) injection of therapeutics, including insulin and human growth hormones (HGH), Nanopass™ 34G offers the quality and supply reliability needed to meet drug developers’ toughest parenteral delivery challenges and product commercialization goals.   This product exemplifies our commitment to enhance the patient experience by using our core capabilities.

_{1 Based on research by Terumo Corporation in November 2020}

_{Please note that Nanopass ™ 34G is not available in USA and Canada.}

Immucise™ Intradermal Injection System

Terumo’s Immucise™ Intradermal Injection System is designed to deliver vaccines and other approved drugs to the dermal layer of the skin for improved immune response in comparison to intramuscular or subcutaneous injections¹.  The vertical type intradermal (ID) injection system is applied perpendicular to the skin of the deltoid region of the patient’s arm².

_{1  Intradermal Delivery of Vaccines, A review of the literature and the potential for development for use in low- and middle-income countries, August 27, 2009}

_{2 Shimizu, Sakiko et al. “Performance and usability evaluation of novel intradermal injection device Immucise™ and reanalysis of intradermal administration trials of influenza vaccine for the elderly.” Vaccine vol. 40,6 (2022): 873-879}

Terumo SurGuard™3 Safety Hypodermic Needle